Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | F10 | P00742 | 11/20 | 0.50 |
| ▸ | PLG | P00747 | 5/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388717 | 1.00 | GPR119 (0.53) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL6928672 | 1.00 | GPR119 (0.53) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL7389231 | 0.98 | GPR119 (0.54) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL6929100 | 0.95 | GPR119 (0.52) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL7380462 | 0.95 | GPR119 (0.59) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL6926256 | 0.94 | GPR119 (0.51) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL6923957 | 0.93 | GPR119 (0.51) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL6815738 | 0.92 | F10 (0.59) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL7387778 | 0.92 | F10 (0.59) | GPR119F10PLGPRSS1PRSS2 | |
| SCHEMBL7387783 | 0.92 | F10 (0.59) | GPR119F10PLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020062033-A1 | Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-23 | — | — | US | claimed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | claimed |
| EP-0936215-A1 | PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | claimed |
| US-6515142-B2 | Intermediates of aromatic amidine derivatives which have anticoagulation action | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020062033-A1 | Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-23 | — | — | US | disclosed |
| US-6337405-B1 | MULTISTAGE REACTION OF PYRROLE SUBSTITUTED WITH SULFONATE GROUPS AND HYDROXYPHENYLACETIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6252088-B1 | COUPLING A NITRILE CONTAININ NAPHTHALENE COMPOUND WITH A COMPOUND CONTAINING PROPIONIC ACID GROUP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0936215-A1 | PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062033-A1 | Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives | PROC, F12, F2 | GPR119 4825/4885F10 56/4885PLG 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.